Cellular mechanisms of multidrug resistance of tumor cells - PubMed (original) (raw)
Affiliations
- PMID: 10702644
Free article
Review
Cellular mechanisms of multidrug resistance of tumor cells
A A Stavrovskaya. Biochemistry (Mosc). 2000 Jan.
Free article
Abstract
Multidrug resistance (MDR) is the protection of a tumor cell population against numerous drugs differing in chemical structure and mechanisms of influence on the cells. MDR is one of the major causes of failures of chemotherapy of human malignancies. Recent studies show that the molecular mechanisms of MDR are numerous. Cellular drug resistance is mediated by different mechanisms operating at different steps of the cytotoxic action of the drug from a decrease of drug accumulation in the cell to the abrogation of apoptosis induced by the chemical substance. Often several different mechanisms are switched on in the cells, but usually one major mechanism is operating. The most investigated mechanisms with known clinical significance are: a) activation of transmembrane proteins effluxing different chemical substances from the cells (P-glycoprotein is the most known efflux pump); b) activation of the enzymes of the glutathione detoxification system; c) alterations of the genes and the proteins involved into the control of apoptosis (especially p53 and Bcl-2).
Similar articles
- A new apoptosis inhibitor, CIAPIN1 (cytokine-induced apoptosis inhibitor 1), mediates multidrug resistance in leukemia cells by regulating MDR-1, Bcl-2, and Bax.
Li X, Hong L, Zhao Y, Jin H, Fan R, Du R, Xia L, Luo G, Fan D. Li X, et al. Biochem Cell Biol. 2007 Dec;85(6):741-50. doi: 10.1139/o07-141. Biochem Cell Biol. 2007. PMID: 18059532 - Inhibition of apoptotic proteins causes multidrug resistance in renal carcinoma cells.
Scheltema JM, Romijn JC, van Steenbrugge GJ, Schröder FH, Mickisch GH. Scheltema JM, et al. Anticancer Res. 2001 Sep-Oct;21(5):3161-6. Anticancer Res. 2001. PMID: 11848468 - Multidrug-resistant hela cells overexpressing MRP1 exhibit sensitivity to cell killing by hyperthermia: interactions with etoposide.
Souslova T, Averill-Bates DA. Souslova T, et al. Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1538-51. doi: 10.1016/j.ijrobp.2004.07.686. Int J Radiat Oncol Biol Phys. 2004. PMID: 15590186 - Evolutionary malignant resistance of cells to damaging factors as common biological defence mechanism in neoplastic development. Review of conception.
Monceviciute-Eringiene E. Monceviciute-Eringiene E. J Exp Clin Cancer Res. 2000 Sep;19(3):335-48. J Exp Clin Cancer Res. 2000. PMID: 11144527 Review. - Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer.
Meijerman I, Beijnen JH, Schellens JH. Meijerman I, et al. Cancer Treat Rev. 2008 Oct;34(6):505-20. doi: 10.1016/j.ctrv.2008.03.002. Epub 2008 Apr 14. Cancer Treat Rev. 2008. PMID: 18413281 Review.
Cited by
- Changes in intracellular redox status influence multidrug resistance in gastric adenocarcinoma cells.
Tai DJ, Jin WS, Wu CS, Si HW, Cao XD, Guo AJ, Chang JC. Tai DJ, et al. Exp Ther Med. 2012 Aug;4(2):291-296. doi: 10.3892/etm.2012.591. Epub 2012 May 24. Exp Ther Med. 2012. PMID: 23139717 Free PMC article. - EGFR-mediated G1/S transition contributes to the multidrug resistance in breast cancer cells.
Chen SJ, Luan J, Zhang HS, Ruan CP, Xu XY, Li QQ, Wang NH. Chen SJ, et al. Mol Biol Rep. 2012 May;39(5):5465-71. doi: 10.1007/s11033-011-1347-4. Epub 2011 Dec 17. Mol Biol Rep. 2012. PMID: 22179693 - Cellular pharmacokinetic mechanisms of adriamycin resistance and its modulation by 20(S)-ginsenoside Rh2 in MCF-7/Adr cells.
Zhang J, Zhou F, Wu X, Zhang X, Chen Y, Zha BS, Niu F, Lu M, Hao G, Sun Y, Sun J, Peng Y, Wang G. Zhang J, et al. Br J Pharmacol. 2012 Jan;165(1):120-34. doi: 10.1111/j.1476-5381.2011.01505.x. Br J Pharmacol. 2012. PMID: 21615726 Free PMC article. - Computational Methods in Cooperation with Experimental Approaches to Design Protein Tyrosine Phosphatase 1B Inhibitors in Type 2 Diabetes Drug Design: A Review of the Achievements of This Century.
Campos-Almazán MI, Hernández-Campos A, Castillo R, Sierra-Campos E, Valdez-Solana M, Avitia-Domínguez C, Téllez-Valencia A. Campos-Almazán MI, et al. Pharmaceuticals (Basel). 2022 Jul 14;15(7):866. doi: 10.3390/ph15070866. Pharmaceuticals (Basel). 2022. PMID: 35890163 Free PMC article. Review. - Environmentally responsive peptides as anticancer drug carriers.
Aluri S, Janib SM, Mackay JA. Aluri S, et al. Adv Drug Deliv Rev. 2009 Sep 30;61(11):940-52. doi: 10.1016/j.addr.2009.07.002. Epub 2009 Jul 20. Adv Drug Deliv Rev. 2009. PMID: 19628014 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous